Antibacterials and Antifungals, 2nd Edition

Sales of antibacterials and antifungals worldwide are approaching $26 billion annually, of which $7 billion are injectables. Historically, sales of cephalosporins maintained the largest market share. Recently, however, the introduction of new fluoroquinolones and a ketolide, a new antibiotic class, promise to exceed sales of all other classes. New antibiotics and antifungals, like the echinocandins, will continue to cause rapid shifts in market share as the demand for more effective therapies expands. One hundred of the antibacterial agents on the market today were developed by using variations on just nine basic elements. Today, genomics and high-throughput screening are yielding potential antibiotics and antifungals utilizing previously unknown mechanisms of action. D&MD's Report provides the answers to help pharmaceutical and biotechnology firms develop numerous strategies to exploit their market positions and develop technological strengths.

Over the last decade, the rapid rise in severe and fatal infections caused by drug resistant bacteria has posed a threat to public health globally. In addition, various factors are fostering the emergence of new and more threatening infectious diseases. These factors include:

· Overuse and misuse of antibiotics

· Expanding use of child care facilities

· Aging of the population

· Growth in the immunosuppressed patient population:

· HIV infection

· Organ transplantation

· Chemotherapy

· Globalization of the food supply - Changes in dietary habits, food processing and packaging

New drugs are urgently needed to combat drug-resistant bacteria. More importantly, scientific methods to continually discover replacement drugs are necessary; each time a new antibiotic is developed using approaches popularized in the past 40 years, there will undoubtedly be resistance. New technologies can change this by providing information that can be developed into new antibacterial and antifungal strategies. The future promises great opportunities for innovative companies that remain at the forefront of drug discovery technology. D&MD's Antibacterials and Antifungals Report provides the reader with the tools to stay ahead of the competition.

Unique Benefits of this Report:

Detailed analyses of current industry trends and strategies to provide insight into potential sales and profits for your business.

• Coverage of the latest technologies impacting existing antibacterial compounds, to help identify new opportunities and overcome the issue of resistance.
• New targets for novel antibacterial agents revealed by genomics and their affect on the future of the market.
• In-depth market and technology trends, to assist in future strategic planning and finding opportunities for new collaborations.
• Sales forecasts through 2006 (by antibacterial class) to gauge industry growth and investment strategies.
• Comparisons of key pharmaceutical company alliances to identify successful partnerships and to benchmark future deals.